Polymorphisms CYP2R1 rs10766197 and CYP27B1 rs10877012 in Multiple Sclerosis: A Case-Control Study
Table 1
Sociodemographic and clinical descriptive characteristics in multiple sclerosis patients.
Variable
Multiple sclerosis
Female, (%)
76 (65.5)
Age, (years)
38 (19-66)
Disease characteristics
Disease evolution, (years)
7.5 (1.0-28.0)
EDSS, (score)
3.0 (0.0-7.0)
Progression index, (score)
0.38 (0.0-4.5)
Severe progression (), (%)
39 (33.6)
Low progression (), (%)
77 (66.4)
Serum 25(OH) vitamin D levels, (ng/mL)
18.3 (3.8-50.9)
Sufficient (>30 ng/mL), (%)
14 (12.0)
Insufficient (20-30 ng/mL), (%)
17 (14.7)
Deficient (<20 ng/mL), (%)
85 (73.3)
Treatment
Glatiramer acetate, (%)
39 (33.6)
Interferon, (%)
27 (23.3)
Rituximab, (%)
12 (10.3)
Fingolimod, (%)
11 (9.5)
Dimethyl fumarate, (%)
7 (6.0)
Azathioprine, (%)
5 (4.3)
Natalizumab, (%)
4 (3.5)
No treatment, (%)
11 (9.5)
EDSS: Expanded Disability Status Scale of Kurtzke for Multiple Sclerosis; IP: index progression (EDSS/disease evolution). Qualitative variables were expressed as frequency and percentage. Quantitative variables were expressed as median and min-max.
